Return to NINDS Parkinson’s Disease Research Web

Innovative Funding Mechanisms

Principal Investigator: Biglan, Kevin M
Grant Number: 2L30NS050062-02
Title: Clinically Meaningful Outcomes in Parkinson's Disease

Abstract: Unavailable

Principal Investigator: BOYLAN, LAURA S
Grant Number: 1L30NS049909-01
Title: Emotion/Depression in Epilepsy & Parkinson's Disease

Abstract: Unavailable

Principal Investigator: CARTER, JULIE H
Grant Number: 3U10NS044483-02S1
Title: Parkinson's Disease Neuroprotection Clinical Trial

Abstract: Unavailable

Principal Investigator: DEBBURMAN, SHUBHIK
Grant Number: 3R15NS048508-01S1
Title: Yeast Model for Two Neurodegeneration-Linked Proteins

Abstract: Unavailable

Principal Investigator: DIXON, C EDWARD
Grant Number: 3R01NS033150-09S1
Title: CHRONIC CHANGES IN NEUROTRANSMISSION FOLLOWING TBI

Abstract: Unavailable

Principal Investigator: FETZ, EBERHARD E
Grant Number: 3R01NS012542-29S1
Title: NEURAL CONTROL OF MUSCLE ACTIVITY

Abstract: Unavailable

Principal Investigator: GERHARDT, GREG A
Grant Number: 3P50NS039787-05S1
Title: RESTORATION OF DOPAMINE FUNCTION IN PARKINSON'S DISEASE

Abstract: Unavailable

Principal Investigator: GIBSON, ALAN R
Grant Number: 3R01NS044592-01A2S1
Title: Influence of the Basal Ganglia on Cerebellar Action

Abstract: Unavailable

Principal Investigator: GREENAMYRE, JOHN T
Grant Number: 5T32NS007480-05
Title: TRAINING IN TRANSLATIONAL RESEARCH IN NEUROLOGY

Abstract: Unavailable

Principal Investigator: GRIGGS, ROBERT C
Grant Number: 5T32NS007338-15
Title: EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE

Abstract: Unavailable

Principal Investigator: HAMILL, ROBERT W
Grant Number: 3U10NS044501-02S1
Title: Parkinson Disease Neuroprotection Clinical Trial

Abstract: Unavailable

Principal Investigator: IACOVITTI, LORRAINE M
Grant Number: 3R21NS043705-02S1
Title: Neural Stem Cells Grafts in Primate Models of Parkinsons

Abstract: Unavailable

Principal Investigator: ISACSON, OLE
Grant Number: 3P50NS039793-05S1
Title: NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE

Abstract: Unavailable

Principal Investigator: JOHNSON, GAIL V. W.
Grant Number: 3R01NS041744-02S1
Title: Mutant huntingtin compromises mitochondrial function

Abstract: Unavailable

Principal Investigator: JOHNSON, RODNEY L
Grant Number: 3R01NS020036-18S1
Title: Pro-Leu-Gly-NH2 and Dopamine Receptor Modulation

Abstract: Unavailable

Principal Investigator: KELLY, VALERIE E
Grant Number: 1L30NS049916-01
Title: Subthalamic Nucleus Stimulation in Parkinson's

Abstract: Unavailable

Principal Investigator: KURLAN, ROGER M
Grant Number: 1U01NS050095-01
Title: Parkinson's Disease Data Organizing Center

Abstract: In response to RFA-NS-NS-05-001, we propose to establish a Parkinson's Disease Data Organizing Center (PD-DOC) at the University of Rochester. In keeping with the RFA, the PD-DOC will: 1) establish, maintain and disseminate a shared, central and standardized longitudinal database in support of the prospective collection and analysis of clinical, neuropathological and biologic data from patients with PD and controls, 2) assess and move toward the potential integration of relevant pre-existing databases, 3) assist investigators planning to perform research studies using the shared database, 4) prepare and maintain an up-to-date catalog of research materials at participating sites that might be used for PD research and, 5) coordinate annual meetings of the PD-DOC Steering Committee. The University of Rochester has extensive expertise and resources which will facilitate the development of a highly successful PD-DOC. The PD-DOC will be a critical force in advancing collaborative research in PD. -

Principal Investigator: LANSBURY, PETER T
Grant Number: 3P50NS038375-05S1
Title: FAMILIAL PARKINSON'S DISEASE: CLUES TO PATHOGENESIS

Abstract: Unavailable

Principal Investigator: LEEHEY, MAUREEN A
Grant Number: 3U10NS044479-02S1
Title: U Colorado Parkinson's Disease Clinical Research

Abstract: Unavailable

Principal Investigator: MCMURRAY, CYNTHIA T
Grant Number: 3R01NS040738-04S1
Title: TRAFFICKING DEFECTS IN HUNTINGTONS DISEASE

Abstract: Unavailable

Principal Investigator: Montine, Thomas J
Grant Number: 5R01NS048595-02
Title: Dementia with Lewy Bodies: A Collaborative Study

Abstract: Patients with the pathologic diagnosis of Alzheimer's disease (AD) commonly (approximately 30 to 60%) have concomitant Lewy body (LB) formation as detected with o_-synuclein immunohistochemical analysis of extra-nigral sites. These patients with AD/LB, along with a much less common dementia characterized by LB formation alone, are currently classified as having Dementia with Lewy Bodies (DLB). There is substantial clinical and pathologic heterogeneity among patients with DLB, thwarting efforts to understand fully the significance of distinguishing AD from DLB and strongly suggesting further distinct subgroups within what is currently called DLB. Here we propose to test the hypothesis that DLB differs from AD at clinical, pathologic, molecular genetic, and biochemical levels, and that these same criteria may be used to discem multiple distinct subgroups of DLB. We will expand an already functioning cooperative study among five Alzheimer Disease Centers (ADC) across the United States: Oregon Health & Science University, University of California at San Diego, University of Pennsylvania, University of Pittsburgh, and University of Washington. We propose to collect clinical and neuropathological data as well as banked tissue from approximately 100 age-matched controls, 250 patients with AD, and 250 patients with DLB. We estimate collection of 20, 50, and 50, respectively, additional cases for each year of this project. Using the robust design of patient data and material from five separate ADCs and biostatistical support from the National Alzheimer's Coordinating Center (NACC), we will test our hypothesis by pursuing these specific aims: to distinguish controls, AD, and DLB, and as well as DLB subgroups by determining (1) clinical and pathological features, (2) characteristics of candidate genes, (3) quantitative differences in oxidative damage, and (4) alterations in both soluble and insoluble forms of tan, A[3, and (z-synuclein. Successful completion of this project will solidify our understanding of DLB and provide a foundation for future clinical and molecular studies of this second most common form of dementia. Specifically, this project will establish a National DLB Resource, including a database of clinico-pathologic data, as well as an inventory of DNA samples and frozen brain tissue. This resource will be made available for future investigations of DLB.-

Principal Investigator: MUZYCZKA, NICHOLAS
Grant Number: 3P01NS036302-06A1S1
Title: Adeno-Associated Virus Gene Transfer to Nervous System

Abstract: Unavailable

Principal Investigator: RACETTE, BRAD A
Grant Number: 3U10NS044455-02S1
Title: PARKINSON DISEASE NEUROPROTECTIVE TRIAL:CLINICAL CENTER

Abstract: Unavailable

Principal Investigator: RON, DAVID
Grant Number: 3R21NS043628-02S1
Title: Endoplasmic Reticulum Stress and Parkinson's Disease

Abstract: Unavailable

Principal Investigator: ROSS, GEORGE WEBSTER
Grant Number: 3U10NS044448-02S1
Title: Parkinson's Disease Neuroprotection Trial: Hawaii Center

Abstract: Unavailable

Principal Investigator: SAGE, JACOB I
Grant Number: 3U10NS044415-02S1
Title: Parkinson's Disease Neuroprotection Clinical Trial

Abstract: Unavailable

Principal Investigator: TILLEY, BARBARA C.
Grant Number: 3U01NS043127-04S1
Title: Parkinson's Disease Clinical Trial: Statistical Center

Abstract: Unavailable

Principal Investigator: TRAYNELIS, STEPHEN F
Grant Number: 3R01NS036654-06S1
Title: Control of glutamate receptor activation

Abstract: Unavailable

Principal Investigator: Traynelis, Stephen F.
Grant Number: 3R01NS036654-07S1
Title: Control of glutamate receptor activation

Abstract: Unavailable

Principal Investigator: VAN DER WALT, JOELLE
Grant Number: 1L30NS050033-01
Title: Mitochondrial dysfunction in Parkinson's disease

Abstract: Unavailable

Principal Investigator: WATTS, RAY L
Grant Number: 3U10NS044547-03S1
Title: UAB PD Neuroprotection Clinical Trial Cent*

Abstract: Unavailable

Principal Investigator: WOOTEN, GEORGE F
Grant Number: 3P50NS039788-05S1
Title: MITOCHONDRIAL ETIOLOGIES OF PARKINSON'S DISEASE

Abstract: Unavailable

Principal Investigator: YOUNG, ANNE B
Grant Number: 3P50NS038372-05S2
Title: MGH/MIT PARKINSONS DISEASE RESEARCH CENTER

Abstract: Unavailable

Principal Investigator: ZHOU, JIANHUA
Grant Number: 5R01NS041665-05
Title: SMN associated proteins and compounds for SMA therapy

Abstract: The autosomal recessive spinal muscular atrophy (SMA) is one of the most common genetic causes of infant death. In SMA, there is anterior horn cell death and muscle weakness. Deletions or mutations in the survival motor neuron gene, SMN, are responsible for the disease. There are two SMN genes. However, only telomeric copy (SMNt or SMNI) causes disease. Due to a single nucleotide difference, T in the second gene SMN2 from C in SMNI, the majority of SMN2 mRNA or protein skips exon7, resulting in an unstable SMNA7 protein and reduction of its oligomerization ability. Therefore, the presence of the SMN2 gene in SMA patients can not compensate for the loss of the SMNI gene. To understand the pathogenesis of SMA, the first goal of this proposal is to use the yeast two-hybrid screens to identify SMN interacting proteins, particularly those from motor neurons. The interactions will be further characterized by other complementary methods including mammalian two hybrid assays, in vitro binding assays and in vivo co-immunoprecipitation assays. The biological significance of interactions between SMN and its interactors will be investigated in cell lines, and as long-term goals, in animal models. The second goal of this proposal is to develop cell-based systems for therapeutic studies of SMA based on the hypothesis that increasing of total or full-length SMN protein from SMN2 would reduce the severity of SMA. Stable cell lines and transgenic mice expressing exon 7 splicing cassettes with reporters such as GFP, luciferase or P-lactamase will be established. Both high and low throughput screening (HTS, LTS) will be used to identify small molecules to promote inclusion of exon 7 in SMN2 mRNA and protein. These compounds will be tested in SMA mouse models. Signal pathways and other mechanisms that regulate RNA splicing of SMN genes will be investigated. 1 ZNS1 SRB R(01) 3 1 R01 NS41665-01 DECEMBER 13-14, 2000 ZHOU, DR. JIANHUA -

Principal Investigator: ZIGMOND, MICHAEL J
Grant Number: 3P50NS019608-19A1S1
Title: Neuroprotection and early detection in PD

Abstract: Unavailable